Table 2.
Preclinical studies of SGLT2is for the treatment of DM or DM-related diseases
| Medicine | Generic Name | First Author | Year | Disease | Model | Findings | Ref. |
|---|---|---|---|---|---|---|---|
| SGLT2is | Dapagliflozin | Lee, T.M. | 2017 | MI | Rat | Dapagliflozin attenuated myocardial fibrosis in rats after MI | [95] |
| Terami, N. | 2014 | T2DM | Mouse | Dapagliflozin significantly reduced macrophage infiltration and expression of inflammation and oxidative stress genes in the kidneys of T2DM mice | [101] | ||
| Ye, Y. | 2017 | DCM | Mouse | Dapagliflozin inhibited Nlrp3/ASC inflammasome activation and attenuated DCM in T2DM mice | [107] | ||
| Empagliflozin | Xu, L. | 2017 | Obesity | Mouse | Empagliflozin improved insulin sensitivity | [99] | |
| Oelze, M. | 2014 | T1DM | Rat | Empagliflozin ameliorated oxidative stress and inflammatory response in T1DM rats | [102] | ||
| Kern, M. | 2016 | DM | Mouse | Empagliflozin improved insulin sensitivity in DM mice | [108] | ||
| Habibi, J. | 2017 | DM | Mouse | Empagliflozin improved cardiac diastolic function in a female mouse model of DM | [109] |
MI myocardial infarction, ASC apoptosis-associated speck-like protein containing a CARD